首页> 外文期刊>Arzneimittel-Forschung: =Drug Research >Synthesis and antimicrobial activity of 4-carbethoxymethyl-2-((alpha-haloacyl)amino) thiazoles and 5-nonsubstituted/substituted 2-((4-carbethoxymethylthiazol-2-yl)imino)-4-thiazolidinones.
【24h】

Synthesis and antimicrobial activity of 4-carbethoxymethyl-2-((alpha-haloacyl)amino) thiazoles and 5-nonsubstituted/substituted 2-((4-carbethoxymethylthiazol-2-yl)imino)-4-thiazolidinones.

机译:4-甲乙氧基甲基-2-((α-卤代酰基)氨基)噻唑和5-非取代/取代的2-((4-乙氧基甲基噻唑-2-基)亚氨基)-4-噻唑烷酮的合成和抗菌活性。

获取原文
获取原文并翻译 | 示例
           

摘要

4-Carbethoxymethyl-2-[(chloroacetyl/alpha-chloropropionyl/al pha- bromobutyryl/alpha-chloro-(alpha-phenylacetyl)amino]thiazoles (I-IV) were synthesized by reacting 4-carbethoxymethyl-2-aminothiazole with chloroacetyl chloride, alpha-chloropropionyl chloride, alpha-bromobutyryl bromide and alpha-chloro-alpha-phenylacetyl chloride, respectively. Furthermore, I-IV were refluxed with ammonium thiocyanate to give 2-[(4-carbethoxymethylthiazol-2-yl)imino]-4-thiazolidinones (V-VIII). V was refluxed with various aromatic aldehydes to give 5-arylidene-2-[(4-carbethoxymethylthiazol-2-yl)imino]-4-t hiazolidinones (IX-XIV). The structures of synthesized compounds were confirmed by elemental analyses, hydrolysis, UV, IR, 1H-NMR and EI mass spectral data. The antimicrobial activities of the compounds were assessed by microbroth dilution technique using Mueller-Hinton broth and Mueller-Hinton Agar. In this study, Staphylococcus aureus ATCC 6538, Staphylococcus epidermidis ATCC 12228, Escherichia coli ATCC 8739, Klebsiella pneumoniae ATCC 4352, Pseudomonas aeruginosa ATCC 1539, Salmonella typhi, Shigella flexneri, Proteus mirabilis and Candida albicans ATCC 10231 were used as test microorganisms. Among the tested compounds, XI and XIV showed activity against S. aureus (MIC: 78 micrograms/ml, 1.6 micrograms/ml), whereas compound V had an activity against S. flexneri (MIC: 39 micrograms/ml) and compound I against C. albicans (MIC: 125 (micrograms/ml). Compounds I, IV-XIV were also evaluated for antituberculosis activity against Mycobacterium tuberculosis H37Rv using the BACTEC 460 radiometric system and BACTEC 12B medium. Only compounds I and XIV showed 86% and 67% inhibition in the primary screen.
机译:通过使4-碳乙氧基甲基-2-氨基噻唑与氯乙酰氯反应合成了4-甲氧乙氧基甲基-2-[((氯乙酰基/α-氯丙酰基/α-溴丁酰基/α-氯-(α-苯基乙酰基)氨基]噻唑)(I-IV) ,α-氯丙酰氯,α-溴丁酰溴和α-氯-α-苯基乙酰氯,然后将I-IV与硫氰酸铵回流,得到2-[((4-乙氧基甲基噻唑-2-基)亚氨基] -4 -噻唑烷酮(V-VIII).V与各种芳族醛回流,得到5-亚芳基-2-[((4-乙氧甲基甲基噻唑-2-基)亚氨基] -4-t-偶氮利丁酮(IX-XIV)。通过元素分析,水解,UV,IR,1H-NMR和EI质谱数据确认了这些化合物,并使用Mueller-Hinton肉汤和Mueller-Hinton琼脂通过微泡稀释技术评估了化合物的抗菌活性。金黄色葡萄球菌ATCC 6538,表皮葡萄球菌ATCC 12228,大肠杆菌将ATCC 8739,肺炎克雷伯菌ATCC 4352,铜绿假单胞菌ATCC 1539,伤寒沙门氏菌,弗氏志贺氏菌,变形杆菌和白色念珠菌ATCC 10231用作测试微生物。在测试的化合物中,XI和XIV表现出抗金黄色葡萄球菌的活性(MIC:78微克/毫升,1.6微克/毫升),而化合物V具有抗弗氏链球菌的活性(MIC:39微克/毫升),化合物I具有抗金葡菌的活性。白色念珠菌(MIC:125(微克/毫升)。还使用BACTEC 460辐射系统和BACTEC 12B培养基评估了化合物I,IV-XIV对结核分枝杆菌H37Rv的抗结核活性。仅化合物I和XIV分别显示86%和67初步筛选中的抑制百分比。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号